<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00911807</url>
  </required_header>
  <id_info>
    <org_study_id>EBE-031010</org_study_id>
    <nct_id>NCT00911807</nct_id>
  </id_info>
  <brief_title>Comparative Study to Test Safety and Efficacy of Neurotrophic and Cholinergic Treatment of Alzheimer's Disease</brief_title>
  <acronym>Combi</acronym>
  <official_title>A Randomized, Double-Blind, Clinical Trial to Compare the Safety and Efficacy of Cerebrolysin and Aricept (Donepezil) and a Combination Therapy in Patients With Probable Alzheimer's Disease (AD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ever Neuro Pharma GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>acromion GmbH</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Ever Neuro Pharma GmbH</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study was performed to compare the safety and efficacy of Cerebrolysin (10 mililiters
      [ml]), Aricept (10 miligrams [mg]), and a combination of both treatments on cognitive
      performance and global function in patients with probable Alzheimer's Disease (AD). It should
      also be assessed if the treatments have a positive effect on activities of daily living and
      neuropsychiatric symptoms.

      Oral treatment with Aricept or Placebo was given once daily throughout the study. Intravenous
      treatment with Cerebrolysin or Placebo was given once daily for 5 days per week during week 1
      to 4 and during week 13 to 16 of the study. During the study patients had six visits at the
      hospital for evaluation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Endogenous neurotrophic factors, also called neurotrophins, are signaling molecules in
      various cellular pathways and allow proper neuronal function, survival and regeneration.
      Sufficient supply is therefore regarded as a pre-requisite for neuronal maintenance but
      sudden or chronic pathological changes result in an imbalance of this regulatory system.

      Cerebrolysin is a peptide preparation acting in a similar way like endogenous neurotrophic
      factors. Due to its pleiotropic effects - neuroprotection, neuronal survival, neuroplasticity
      and neurogenesis -, Cerebrolysin is regarded as potential therapeutic tool in complex
      diseases like stroke or dementia. In contrast to naturally occurring neurotrophic factors,
      neuropeptides of Cerebrolysin enter the brain parenchyma by crossing the blood-brain barrier
      after peripheral (intravenous [IV]) administration.

      Another treatment approach for Alzheimer's disease targets the cholinergic system to increase
      cortical acetylcholine. One of these drugs is the anticholinesterase donepezil (Aricept).
      However, anticholinesterases seem to provide only symptomatic benefit for a limited period
      and not to influence the progression of the disease. In view of the different mechanisms of
      action and clinical profile of Cerebrolysin and Aricept, a combination therapy of both may
      provide synergistic treatment effects. The combination of a treatment targeting the
      neurotrophic axis (Cerebrolysin) with a treatment to improve cholinergic neurotransmission
      (Aricept) can arguably be expected to provide additional benefits to AD patients.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2004</start_date>
  <completion_date type="Actual">April 2008</completion_date>
  <primary_completion_date type="Actual">April 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in Alzheimer's Disease Assessment Scale Cognitive Subpart (Extended Version) (ADAS-COG+) at Week 28</measure>
    <time_frame>baseline and week 28</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical Interview-Based Impression of Change (CIBIC+) Score</measure>
    <time_frame>week 28</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline for ADAS-COG+</measure>
    <time_frame>week 4, 12, 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ADAS-COG+ Responders</measure>
    <time_frame>week 4, 12, 16, 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline for Original ADAS-COG</measure>
    <time_frame>week 4, 12, 16, 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CIBIC+ Score</measure>
    <time_frame>week 4, 12, 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CIBIC+ Responders</measure>
    <time_frame>week 4, 12, 16, 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Interview-Based Impression of Severity (CIBIS+) Score</measure>
    <time_frame>week 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline for Alzheimer's Disease Cooperative Study Activities of Daily Living (ADCS-ADL)</measure>
    <time_frame>week 16, 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Total Score for Neuropsychiatric Inventory (NPI)</measure>
    <time_frame>week 16, 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Combined Responders, i.e. Response in ADAS-COG+ and CIBIC+</measure>
    <time_frame>week 4, 12, 16, 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Experiences, Vital Signs, Physical and Neurological Examinations, Laboratory Tests (Hematology, Clinical Chemistry , Urinalysis, Electrocardiogram [ECG])</measure>
    <time_frame>Baseline, week 4, 12, 16, 28</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">217</enrollment>
  <condition>Alzheimer Disease</condition>
  <arm_group>
    <arm_group_label>Cerebrolysin + donepezil</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Cerebrolysin + placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Donepezil + placebo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cerebrolysin + donepezil</intervention_name>
    <description>Cerebrolysin (10 ml) was given as IV infusion on five days per week for four consecutive weeks (week 1-4) with repetition of this treatment course (week 13-16) after a two-months treatment free interval, accounting for a total of 40 infusions.
Donepezil was given PO once daily during the whole study duration (28 weeks). After four weeks the daily dosage was increased from 5 mg to 10 mg.</description>
    <arm_group_label>Cerebrolysin + donepezil</arm_group_label>
    <other_name>Brand name for donepezil: Aricept</other_name>
    <other_name>Brand name for Cerebrolysin: Cerebrolysin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cerebrolysin + placebo</intervention_name>
    <description>Cerebrolysin (10 ml) was given as IV infusion on five days per week for four consecutive weeks (week 1-4) with repetition of this treatment course (week 13-16) after a two-months treatment free interval, accounting for a total of 40 infusions.
Placebo for donepezil was given PO once daily during the whole study duration (28 weeks).</description>
    <arm_group_label>Cerebrolysin + placebo</arm_group_label>
    <other_name>Brand name for Cerebrolysin: Cerebrolysin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Donepezil + placebo</intervention_name>
    <description>Placebo for Cerebrolysin was given as IV infusion on five days per week for four consecutive weeks (week 1-4) with repetition of this treatment course (week 13-16) after a two-months treatment free interval, accounting for a total of 40 infusions.
Donepezil was given PO once daily during the whole study duration (28 weeks). After four weeks the daily dosage was increased from 5 mg to 10 mg.</description>
    <arm_group_label>Donepezil + placebo</arm_group_label>
    <other_name>Brand name for donepezil: Aricept</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria

          -  Diagnosis of probable AD (Diagnostic and Statistical Manual of Mental Disorders, 4th
             revision [DSM-IV], National Institute of Neurological and Communicative Disorders and
             Stroke and the Alzheimer's Disease and Related Disorders Association [NINCDS-ADRDA])

          -  Mini-Mental-State-Examination (MMSE) of 12-25, inclusive

          -  Modified Hachinski score ≤4

          -  Computed tomography (CT) or magnetic resonance imaging (MRI) scan within 12 months
             prior to screening without evidence of infection, infarction, or other focal lesions
             and without clinical symptoms suggestive of intervening neurological disease. Patients
             who have had a single, clinically silent lacunar infarct are eligible provided the
             lacunar infarct is not felt to be responsible for the patient's symptoms, is &lt;1
             centimeter (cm) maximal diameter in any dimension, is not present in hippocampus of
             either hemisphere, head of the left caudate, or the dorsomedial region of the left
             thalamus. Subjects with scans showing atrophy, ventricular enlargement or mild to
             moderate white matter changes (involving up to approximately 25% of hemispheric white
             matter) are eligible if the study is otherwise normal.

          -  Hamilton Depression Scale score of ≤15

          -  Adequate visual and auditory acuity to allow neuropsychological testing

          -  Ability to attempt all sections of the Alzheimer's Disease Assessment Scale Cognitive
             Subpart (extended version)(ADAS-cog+)

          -  Good general health without additional diseases expected to interfere with the study

          -  Normal B12, folic acid, venereal disease research laboratory (VDRL), and
             thyroid-stimulating hormone (TSH) or without any clinically significant laboratory
             abnormalities that would be expected to interfere with the study

          -  Electrocardiogram (ECG) and chest x-ray (if clinically necessary per Investigator)
             without clinically significant laboratory abnormalities that would be expected to
             interfere with the study

          -  Patient is not institutionalized

          -  Patient is not pregnant, lactating, or of childbearing potential

          -  Sufficient language skills to complete all testing without assistance of a language
             interpreter

          -  Responsible caregiver being present during administration of study drug, monitor the
             patient's compliance with study procedures and adverse events, and accompany the
             patient to all clinic visits

          -  Written informed consent obtained from the patient and caregiver prior to entry into
             the study

        Exclusion criteria

          -  Any clinically significant laboratory abnormalities on the battery of screening tests

          -  Patients who in the past have not tolerated treatment with 10 mg Aricept or treatment
             with a corresponding dose of another cholinesterase inhibitor

          -  Severe psychotic features, depression, agitation or behavioral problems within the
             last three months that could lead to difficulty complying with the protocol

          -  Any significant systemic illness or unstable medical condition that could lead to
             difficulty complying with the protocol

          -  Patients who in the Investigator's opinion would not comply with study procedures

          -  Any significant neurological disease other than Alzheimer's Disease, within the past
             five years, or with residual effects

          -  Delusional symptoms are often characteristic of Alzheimer's Disease, but patients with
             symptoms so pronounced that they warrant an alternative diagnosis are excluded

          -  History of alcohol or substance abuse or dependence within the past two years (DSM-IV)

          -  History of schizophrenia (DSM-IV)

          -  Patients with a history of systemic cancer within the past two years are excluded

          -  History of myocardial infarction in the past year or unstable or severe cardiovascular
             disease, including uncontrolled hypertension

          -  Uncontrolled insulin-requiring diabetes or non-insulin dependent diabetes mellitus
             (Haemoglobin A1c [HBA1c] &gt; 10.0)

          -  Use of:

               -  systemic corticosteroids for more than one week within three months prior to
                  Baseline (BL)

               -  Anti-Parkinsonian agents within two months prior to baseline (BL)

               -  Approved or investigational Cholinesterase Inhibitors within 30 days or five
                  half-lives, whichever is longer, prior to BL

               -  Memantine or other N-methyl-D-aspartic acid (NMDA) antagonists within 30 days or
                  five half-lives, whichever is longer, prior to BL

               -  Treatment with high potency neuroleptics or narcotic analgesics within four weeks
                  prior to BL

               -  Cimetidine within four weeks prior to BL

               -  Sedatives more frequently than two times per week for sleep within four weeks
                  prior to BL
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>51 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ánton X Àlvarez, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>EuroEspes Biomedical Research Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Herbert Moessler, PhD</last_name>
    <role>Study Director</role>
    <affiliation>EBEWE Pharma</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centro Geriátrico Fuente Salinas</name>
      <address>
        <city>Granada</city>
        <zip>18340</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>EuroEspes Biomedical Research Centre</name>
      <address>
        <city>La Coruna</city>
        <zip>15166</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clínica de Memoria</name>
      <address>
        <city>Málaga</city>
        <zip>29005</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>June 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 7, 2009</study_first_submitted>
  <study_first_submitted_qc>April 7, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 2, 2009</study_first_posted>
  <results_first_submitted>April 7, 2009</results_first_submitted>
  <results_first_submitted_qc>April 7, 2009</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 2, 2009</results_first_posted>
  <last_update_submitted>June 4, 2009</last_update_submitted>
  <last_update_submitted_qc>June 4, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 10, 2009</last_update_posted>
  <responsible_party>
    <name_title>Dr. Philipp Novak</name_title>
    <organization>EBEWE Neuro Pharma</organization>
  </responsible_party>
  <keyword>Clinical Trial, Phase II</keyword>
  <keyword>Randomized Controlled Trial</keyword>
  <keyword>Multicenter Study</keyword>
  <keyword>Cerebrolysin</keyword>
  <keyword>Donepezil</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Donepezil</mesh_term>
    <mesh_term>Cerebrolysin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Dates of recruitment period: 18-OCT-2004 - 29-OCT-2007 Type of location: hospital (La Coruna), institutions specialized on cognitive disorders (Granada, Malaga)</recruitment_details>
      <pre_assignment_details>Patients were excluded from the trial before assignment to groups when not all inclusion criteria were met or when exclusion criteria were applicable.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Cerebrolysin + Donepezil</title>
        </group>
        <group group_id="P2">
          <title>Cerebrolysin</title>
        </group>
        <group group_id="P3">
          <title>Donepezil</title>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="72"/>
                <participants group_id="P2" count="70"/>
                <participants group_id="P3" count="75"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="55"/>
                <participants group_id="P2" count="52"/>
                <participants group_id="P3" count="52"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="18"/>
                <participants group_id="P3" count="23"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Organizational reasons</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Cerebrolysin + Donepezil</title>
        </group>
        <group group_id="B2">
          <title>Cerebrolysin</title>
        </group>
        <group group_id="B3">
          <title>Donepezil</title>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="72"/>
            <count group_id="B2" value="70"/>
            <count group_id="B3" value="75"/>
            <count group_id="B4" value="217"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="24.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63"/>
                    <measurement group_id="B2" value="61"/>
                    <measurement group_id="B3" value="69"/>
                    <measurement group_id="B4" value="193.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="74.5" spread="8.3"/>
                    <measurement group_id="B2" value="75.1" spread="7.6"/>
                    <measurement group_id="B3" value="76.0" spread="7.7"/>
                    <measurement group_id="B4" value="75.2" spread="7.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60"/>
                    <measurement group_id="B2" value="51"/>
                    <measurement group_id="B3" value="58"/>
                    <measurement group_id="B4" value="169.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="17"/>
                    <measurement group_id="B4" value="48.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Spain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="72"/>
                    <measurement group_id="B2" value="70"/>
                    <measurement group_id="B3" value="75"/>
                    <measurement group_id="B4" value="217.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Alzheimer’s Disease Assessment Scale Cognitive Subpart (Extended Version) (ADAS-COG+) at Week 28</title>
        <description>The ADAS-cog+ is a validated, widely used, 14 item psychometric instrument for testing cognitive functions with increased sensitivity in detecting changes in milder patients compared to the original ADAS-cog. It has a maximum score of 85 with a higher score indicating impairment and was assessed by a qualified neuropsychologist.</description>
        <time_frame>baseline and week 28</time_frame>
        <population>Analysis was intention to treat</population>
        <group_list>
          <group group_id="O1">
            <title>Cerebrolysin + Donepezil</title>
          </group>
          <group group_id="O2">
            <title>Cerebrolysin</title>
          </group>
          <group group_id="O3">
            <title>Donepezil</title>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Alzheimer’s Disease Assessment Scale Cognitive Subpart (Extended Version) (ADAS-COG+) at Week 28</title>
          <description>The ADAS-cog+ is a validated, widely used, 14 item psychometric instrument for testing cognitive functions with increased sensitivity in detecting changes in milder patients compared to the original ADAS-cog. It has a maximum score of 85 with a higher score indicating impairment and was assessed by a qualified neuropsychologist.</description>
          <population>Analysis was intention to treat</population>
          <units>points on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="67"/>
                <count group_id="O2" value="64"/>
                <count group_id="O3" value="66"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.348" spread="5.993"/>
                    <measurement group_id="O2" value="-1.711" spread="7.500"/>
                    <measurement group_id="O3" value="-1.246" spread="6.147"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The null-hypothesis stated no differences between the three treatment groups regarding the mean change from baseline in ADAS-cog+ at week 28. A sample size of approximately 60 evaluable patients per treatment arm was estimated to allow for the detection of a significant group difference of two points in ADAS-cog+ week 28 change score (standard deviation [SD] 3.3) between the three groups with a power of &gt; 80% and a probability level of alpha = 0.05 (two-sided).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6348</p_value>
            <p_value_desc>ANCOVA F-test. The study was designed to show significant differences in each of the two primary variables. No adjustment for multiple testing was needed and all tests were done with retention of the full two-sided alpha-level of 0.05.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA with the week 28 ADAS-cog+ change score as dependent variable and the ADAS-cog+ baseline score as a covariate.</method_desc>
            <param_type>Mean Square (Factor Treatment)</param_type>
            <param_value>19.59</param_value>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Multiple testing of individual null hypotheses that control for the overall significance level alpha = 0.05 were performed by using the 'closed testing procedure'</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5830</p_value>
            <p_value_desc>No adjustment for multiple testing was needed and all tests were done with retention of the full two-sided alpha-level of 0.05.</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>Comparisons between all pair of means were performed with two-sample t-tests within the ANCOVA model.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.630</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-2.891</ci_lower_limit>
            <ci_upper_limit>1.630</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Multiple testing of individual null hypotheses that control for the overall significance level alpha = 0.05 were performed by using the 'closed testing procedure'.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3434</p_value>
            <p_value_desc>No adjustment for multiple testing was needed and all tests were done with retention of the full two-sided alpha-level of 0.05.</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>Comparisons between all pair of means were performed with two-sample t-tests within the ANCOVA model.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-1.080</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-3.324</ci_lower_limit>
            <ci_upper_limit>1.163</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Multiple testing of individual null hypotheses that control for the overall significance level alpha = 0.05 were performed by using the 'closed testing procedure'.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6962</p_value>
            <p_value_desc>No adjustment for multiple testing was needed and all tests were done with retention of the full two-sided alpha-level of 0.05.</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>Comparisons between all pair of means were performed with two-sample t-tests within the ANCOVA model.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.450</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-2.719</ci_lower_limit>
            <ci_upper_limit>1.819</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Clinical Interview-based Impression of Change (CIBIC+) Score</title>
        <time_frame>week 28</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline for ADAS-COG+</title>
        <time_frame>week 4, 12, 16</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>ADAS-COG+ Responders</title>
        <time_frame>week 4, 12, 16, 28</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline for Original ADAS-COG</title>
        <time_frame>week 4, 12, 16, 28</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>CIBIC+ Score</title>
        <time_frame>week 4, 12, 16</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>CIBIC+ Responders</title>
        <time_frame>week 4, 12, 16, 28</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Interview-based Impression of Severity (CIBIS+) Score</title>
        <time_frame>week 28</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline for Alzheimer's Disease Cooperative Study Activities of Daily Living (ADCS-ADL)</title>
        <time_frame>week 16, 28</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Total Score for Neuropsychiatric Inventory (NPI)</title>
        <time_frame>week 16, 28</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Combined Responders, i.e. Response in ADAS-COG+ and CIBIC+</title>
        <time_frame>week 4, 12, 16, 28</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adverse Experiences, Vital Signs, Physical and Neurological Examinations, Laboratory Tests (Hematology, Clinical Chemistry , Urinalysis, Electrocardiogram [ECG])</title>
        <time_frame>Baseline, week 4, 12, 16, 28</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Cerebrolysin + Donepezil</title>
        </group>
        <group group_id="E2">
          <title>Cerebrolysin</title>
        </group>
        <group group_id="E3">
          <title>Donepezil</title>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 10.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1"/>
                <counts group_id="E2" subjects_affected="1"/>
                <counts group_id="E3" subjects_affected="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="68"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="68"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Hip fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="68"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="68"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="68"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="68"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 10.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="45"/>
                <counts group_id="E2" subjects_affected="40"/>
                <counts group_id="E3" subjects_affected="46"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="67"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="65"/>
                <counts group_id="E3" events="7" subjects_affected="7" subjects_at_risk="68"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="67"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="65"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="68"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="67"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="68"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="67"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="65"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="68"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="67"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="65"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="68"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="67"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="65"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="68"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="67"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="65"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="68"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="67"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="65"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="68"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Agitation</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="67"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="65"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="68"/>
              </event>
              <event>
                <sub_title>Dysthymic disorder</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="67"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="65"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="68"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="67"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="65"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="68"/>
              </event>
              <event>
                <sub_title>Confusional state</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="67"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="65"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="68"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="67"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="65"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="68"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Philipp Novak</name_or_title>
      <organization>EBEWE Pharma</organization>
      <phone>01143-7665-8123 ext 733</phone>
      <email>philipp.novak@ebewe.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

